Frankfurt am Main, August 21, 2024. Hesse's Economics Minister Kaweh Mansoori (SPD) and the Mayor of Offenbach, Dr. Felix Schwenke (SPD), visited BioSpring GmbH in Frankfurt, Germany, to learn more about the production of innovative active ingredients for future medicines and how this advancement continues to drive the company's economic growth.
The discussions at BioSpring's Frankfurt headquarters focused specifically on future technologies such as the production of innovative, highly effective nucleic acid-based active pharmaceutical ingredients, and the added value that can be generated from such special biotechnology applications.
“We are delighted to be able to continue the dialogue with politicians through the visit of Minister Mansoori and Mayor Schwenke,” said Dr. Sylvia Wojczewski, Chief Executive Officer (CEO) and co-owner of BioSpring. “We want to continue to invest and grow, thereby contributing to economic development in Hesse. With our commitment, we are creating new and attractive jobs in the Rhine-Main region.“
Minister Mansoori and Mayor Schwenke visited BioSpring's clean room production facilities and quality control laboratories in Frankfurt Fechenheim. Minister Mansoori praised BioSpring's positive impact on the state's economy: “I am delighted that BioSpring is successfully manufacturing active pharmaceutical ingredients in Hesse. Here in Fechenheim, BioSpring is an impressive example of innovation. It is a clear signal of the key role that medical biotechnology plays as an industry of the future in Hesse.” Mayor Schwenke commented, “A lot has happened at BioSpring since my last visit. The company is growing and has continuously created new jobs in the region as planned. We strongly support the company's plans to build new production facilities on the innovation campus in Offenbach. This will turn the city into a biotechnology location of international standing. As communicated from the outset, not overnight, but step by step and with a long-term perspective. For us, this is an important building block in further strengthening Offenbach as a business location overall and making it fit for the future.”
BioSpring is one of the world's leading manufacturers of synthetic nucleic acids and partnering with renowned multinational biotech and pharmaceutical companies. BioSpring is the global market leader in the production of molecules used in genome editing. Genome editing specifically corrects genetic defects and therefore has the potential to completely cure genetic diseases with just one treatment - in contrast to conventional therapies, which only combat the symptoms.
BioSpring manufactures exclusively in Germany and has created hundreds of new jobs in the recent years. The company intends to expand further in the coming years and is currently planning the construction of new production facilities on an industrial scale in Offenbach am Main, Germany. In the long term, up to 1,500 jobs are to be created there.
From left to right: Dr. Sylvia Wojczewski, Dr. Felix Schwenke, Kaweh Mansoori
About BioSpring
BioSpring is a contract manufacturer for the biotech and pharmaceutical industries and a global leader in the production and analysis of nucleic acids, which are used in medicine, diagnostics, bioanalytics and research. Oligonucleotides are made up of the same building blocks as human genetic material. BioSpring is the world's leading manufacturer of therapeutic gene scissors (genome editing) used in cell and gene therapy.
The active ingredients produced at BioSpring have the potential to enable therapies for a plethora of untreatable diseases. These include novel compounds for the treatment of cardiovascular, neurological, and metabolic diseases (and more), as well as cancer.
BioSpring was founded in Frankfurt am Main by Dr. Hüseyin Aygün and Dr. Sylvia Wojczewski, who were then doctoral students at Goethe University, and is still owner-managed. The company, which now has over 600 employees, has its production headquarters in Frankfurt-Fechenheim, Germany, as well as a subsidiary in San Diego, USA, and, in the future, an additional 170,000 ft2 production facility in Offenbach am Main, Germany, where up to 1,500 jobs will be created in the long term.
Contact
Dr. Martin Schink, Senior Team Lead Marketing
BioSpring Gesellschaft für Biotechnologie mbH
Alt-Fechenheim 34, 60386 Frankfurt am Main
Phone: +49 (0) 69 66055000
E-Mail: schink@biospring.de